Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_assertion type Assertion NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_head.
- NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_assertion description "[Furthermore, Hsp90 inhibitors 17-AAG [17-(allylamino)-17-demethoxygeldanamycin] and STA-9090 significantly reduced the growth of myeloid leukemia xenografts in vivo and effectively down-regulated the expression of WT1 and its downstream target proteins, c-Myc and Bcl-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_provenance.
- NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_assertion evidence source_evidence_literature NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_provenance.
- NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_assertion SIO_000772 20651072 NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_provenance.
- NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_assertion wasDerivedFrom befree-2016 NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_provenance.
- NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_assertion wasGeneratedBy ECO_0000203 NP827602.RAwU-V5gp-Aolr4N38OuATxblxs6ddjUxHmS4wr9FasFA130_provenance.